These results indicate nuciferine could be an effective supplementary agent with YAP inhibition by the AMPK-mediated down-regulation of HMGCR, which may sensitize pancreatic cancer cells to gemcitabine [20]. The gene discussed is HMGCR; the disease is pancreatic neoplasm.